Financial publications

 

The financial publications section contains the Company’s annual and quarterly reports, corporate presentations held at Investor Relations events as well as the Company’s financial guidance and financial key figures. Further information regarding the Company’s business model and its business segments can be found in the 'About' section of this website.

 

Financial Reports

Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations.

 

Financial Reports Archive

2017

Annual Report

Financial Statements

Separate non-financial group report

Webcast/Conference call regarding the fiscal year 2017 results

Conference Call/Webcast regarding the acquisition of Aptuit

2016

Financial Statements

Conference Call/Webcast regarding strategic collaboration with Celgene

Conference Call/Webcast regarding the offer to acquire Cyprotex

2014

Financial Statements

Conference Call/Webcast announcing negotiations on major collaboration with Sanofi

2011

Annual Report

Financial Statements

Conference call Webcast announcing licence argeement with Roche

Conference call and Webcast announcing the acquisition of Compound Focus, Inc.

Conference call and Webcast announcing the acquisition of Kinaxo

2010

Financial Statements

Conference call and Webcast announcing the alliance with MedImmune

Third Quarter Report

Half Year Report

Conference call and Webcast announcing the acquisition of DeveloGen

First Quarter Report

2009

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2008

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2007

Annual Report

Financial Statements

Third Quarter Report

Half Year Report

First Quarter Report

2006

Annual Report

Financial Statements According to HGB

Third Quarter Report

Second Quarter Report

First Quarter Report

2005

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

New Segmental P&L Statements

2004

Third Quarter Report

Second Quarter Report

First Quarter Report

2003

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2002

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2001

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

2000

Annual Report

Third Quarter Report

Second Quarter Report

First Quarter Report

Oxford Asymmetry International plc 2000 Interim Statement

Oxford Asymmetry International plc 2000 Interim Statement

1999

Annual Report

Third Quarter Report

Oxford Asymmetry International plc Annual Report 1999

Guidance 2018

Guidance 2018
Actual 20172)
Group revenues
More than 30% growth
€ 257.3 m
Adjusted Group EBITDA1)
Improve by approx. 30% compared to 2017
€ 58.4 m
R&D expenses
Approx. € 35-45 m (previously: approx. € 20-30 m) 
€ 17.6 m
Group revenues  
Guidance 2018 More than 30% growth
Actual 20172) € 257.3 m
Adjusted Group EBITDA1)  
Guidance 2018 Improve by approx. 30% compared to 2017
Actual 20172) € 58.4 m
R&D expenses  
Guidance 2018 Approx. € 35-45 m (previously: approx. € 20-30 m) 
Actual 20172) € 17.6 m

1) EBITDA is defined as earnings before interest, taxes, depreciation, and amortisation of intangibles. EBITDA excludes contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result.

2) 2017 figures adjusted from the first time application of IFRS 15

Financial key figures according to IFRS

2017
2016
2017|2016 
Results:
Revenues
T€
257,630
164,507
57%
R&D expenses
T€
(17,614)
(18,108)
(3)%
Operating result
T€
37,495
31,342
20%
Adjusted Group EBITDA1)
T€
57,990
36,225
60%
Net income
T€
23,999
26,839
(11)%
Balance sheet data:
Total stockholders' equity
T€
331,747
213,936
55%
Capital expenditure2)
T€
17,587
10,149
69%
Cash, cash equivalents and investments
T€
91,156
126,270
(28)%
Balance sheet total
T€
667,268
354,1073)
76%
Operating cash flow
T€
10,828
67,360
(84)%
Personnel data:
Employees as of 31 Dec
2,178
1,238
76%
Per share:
Result (basic/diluted)
Euro
0.17/0.16
0.20/0.20
Results:  
2017
2016
2017|2016 
Revenues  
T€
2017 257,630
2016 164,507
2017|2016  57%
R&D expenses  
T€
2017 (17,614)
2016 (18,108)
2017|2016  (3)%
Operating result  
T€
2017 37,495
2016 31,342
2017|2016  20%
Adjusted Group EBITDA1)  
T€
2017 57,990
2016 36,225
2017|2016  60%
Net income  
T€
2017 23,999
2016 26,839
2017|2016  (11)%
 
2017
2016
2017|2016 
Balance sheet data:  
2017
2016
2017|2016 
Total stockholders' equity  
T€
2017 331,747
2016 213,936
2017|2016  55%
Capital expenditure2)  
T€
2017 17,587
2016 10,149
2017|2016  69%
Cash, cash equivalents and investments  
T€
2017 91,156
2016 126,270
2017|2016  (28)%
Balance sheet total  
T€
2017 667,268
2016 354,1073)
2017|2016  76%
Operating cash flow  
T€
2017 10,828
2016 67,360
2017|2016  (84)%
 
2017
2016
2017|2016 
Personnel data:  
2017
2016
2017|2016 
Employees as of 31 Dec  
2017 2,178
2016 1,238
2017|2016  76%
 
2017
2016
2017|2016 
Per share:  
2017
2016
2017|2016 
Result (basic/diluted)  
Euro
2017 0.17/0.16
2016 0.20/0.20
2017|2016 

1) Adjusted for changes in contingent considerations

2) Cash relevant purchase of tangible and intangible assets

3) Modified by the effect of the finalization of Cyprotex’s purchase price allocation in 2017 in accordance with IFRS 3, see Note 4 of the Notes to consolidated financial statements for the year 2017

 

Investor Presentations

Please find below various presentations held at investor conferences or during investor calls available for your download.

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard
TOP